Aceto 'No Longer Requires' CEO Kennally

Aceto has terminated William Kennally’s tenure as president and CEO of the struggling US firm, following deals struck to divest its Rising Pharmaceuticals generics business and chemicals unit as part of bankruptcy proceedings. Meanwhile, the Nasdaq listing has confirmed that Aceto will be delisted in mid-June.

RedWoodenFigure
Kennally Has Been Removed As President And CEO Of Aceto • Source: Shutterstock

Aceto has terminated William Kennally’s employment as president and CEO of the US company, which remains embroiled in bankruptcy proceedings that have included deals to divest a large chunk of its business.

The company recently completed the sale of its Rising Pharmaceuticals generics unit– along with Rising’s subsidiaries and related assets –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business